The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability

The p53 gene is a critical tumor suppressor that is inactivated in a majority of cancers. The central role of p53 in response to stresses such as DNA damage, hypoxia, and oncogene activation underlies this high frequency of negative selection during tumorigenic transformation. Mutations in p53 disrupt checkpoint responses to DNA damage and result in the potential for destabilization of the genome. Consistent with this, p53 mutant cells have been shown to accumulate genomic alterations in cell culture, mouse models, and some human tumors. The relationship between p53 mutation and genomic instability in human osteosarcoma is addressed in this report. Similar to some other primary human tumors, the mutation of p53 correlates significantly with the presence of high levels of genomic instability in osteosarcomas. Surprisingly, osteosarcomas harboring an amplification of the HDM2 oncogene, which inhibits the tumor-suppressive properties of p53, do not display high levels of genomic instability. These results demonstrate that the inactivation of p53 in osteosarcomas directly by mutation versus indirectly by HDM2 amplification may have different cellular consequences with respect to the stability of the genome.

[1]  C. Ostwald,et al.  p53 mutational spectra are different between squamous‐cell carcinomas of the lip and the oral cavity , 2000, International journal of cancer.

[2]  S. Mai,et al.  Genomic instability and apoptosis are frequent in p53 deficient young mice , 1997, Oncogene.

[3]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[4]  M M Weiss,et al.  Comparative genomic hybridisation. , 1999, Molecular pathology : MP.

[5]  D. Smith,et al.  p53 point mutation and survival in colorectal cancer patients. , 1995, Cancer research.

[6]  J. Varley,et al.  Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts , 2000, British Journal of Cancer.

[7]  J. Shah,et al.  Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. , 2001, Cancer research.

[8]  A. Levine,et al.  Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene , 1995, Molecular medicine.

[9]  S. Powell,et al.  Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control , 2000, Oncogene.

[10]  A. Levine,et al.  Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[12]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[13]  D. Malkin,et al.  p53 and the Li-Fraumeni syndrome. , 1993, Cancer genetics and cytogenetics.

[14]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[15]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[16]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[17]  C. Purdie,et al.  Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. , 1994, Oncogene.

[18]  P. Ambros,et al.  Chromosomal regions involved in the pathogenesis of osteosarcomas , 2000 .

[19]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[20]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[21]  M. Oren,et al.  Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2. , 1996, The EMBO journal.

[22]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[23]  R. Katakura,et al.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.

[24]  S. Knuutila,et al.  Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. , 1995, Cancer research.

[25]  M. Ridanpää,et al.  A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[27]  S. Lenk,et al.  Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments. , 2000, Cancer detection and prevention.

[28]  H. von der Maase,et al.  Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. , 2002, Journal of the National Cancer Institute.

[29]  J. Eyfjörd,et al.  p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.

[30]  L. Wiesmüller,et al.  DNA Substrate Dependence of p53-Mediated Regulation of Double-Strand Break Repair , 2002, Molecular and Cellular Biology.

[31]  S. Knuutila,et al.  DNA sequence copy number increase at 8q: A potential new prognostic marker in high‐grade osteosarcoma , 1999, International journal of cancer.

[32]  I. Bièche,et al.  Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer , 1998, International journal of cancer.

[33]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[34]  L. Wiesmüller,et al.  Dissociation of the recombination control and the sequence-specific transactivation function of P53 , 1999, Oncogene.

[35]  W. Foulkes,et al.  MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. , 1995, British Journal of Cancer.

[36]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[37]  H. Liber,et al.  Homologous and Nonhomologous Recombination Resulting in Deletion: Effects of p53 Status, Microhomology, and Repetitive DNA Length and Orientation , 2000, Molecular and Cellular Biology.

[38]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[39]  T. Yagi,et al.  Enhanced proliferative potential in culture of cells from p53-deficient mice. , 1993, Oncogene.

[40]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[41]  V. Challa,et al.  Cerebrovascular Pathology in Alzheimer's Disease and Leukoaraiosis , 2000, Annals of the New York Academy of Sciences.

[42]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[43]  F. Barany,et al.  Mutation Detection in K‐ras, BRCA1, BRCA2, and p53 Using PCR/LDR and a Universal DNA Microarray , 2000, Annals of the New York Academy of Sciences.

[44]  D. Pinkel,et al.  Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.

[45]  A. Levine,et al.  Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein , 1998, The EMBO journal.

[46]  Patrick J. Paddison,et al.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.

[47]  R. Weichselbaum,et al.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. , 1992, Cancer research.

[48]  Genes, chromosomes & cancer , 1995 .

[49]  Robert A. Weinberg,et al.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 , 1994, Nature Genetics.

[50]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[51]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[52]  A. Levine,et al.  The p53 functional circuit. , 2001, Journal of cell science.

[53]  J. Dahm-Daphi,et al.  Loss of wild-type p53 function is responsible for upregulated homologous recombination in immortal rodent fibroblasts. , 2000, International journal of radiation biology.

[54]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[55]  A. Wyllie,et al.  Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability , 1999, Oncogene.

[56]  Emma Jones,et al.  The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma , 2000 .

[57]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[58]  R. Romagnoli,et al.  Malignant tumors of the osteogenic matrix. , 1998, European journal of radiology.

[59]  B. Vogelstein,et al.  Mutational spectra and immunohistochemical analyses of p53 in human cancers. , 1992, Chest.